Skip to main content

Urinary Acidifiers and Alkalinizers

At a glance​

Identify the indication before changing urine pH. Dissolving uric-acid stones, preventing recurrence, correcting systemic acidosis and supporting methenamine activity are different tasks. Follow serum electrolytes and kidney function as well as urine chemistry when prescribing an alkali.[1][6][8]

  • Calcium-phosphate stones do not create a blanket ban on citrate. Hypocitraturia or distal renal tubular acidosis (dRTA) may justify treatment despite an already alkaline urine; monitor the overall metabolic response.[1][31]
  • Diversion patients need ongoing metabolic surveillance; bicarbonate duration is individualized. An early postoperative cohort cannot establish that most patients require lifelong supplementation.[4][32][33]
  • Do not routinely add vitamin C to methenamine. Its clinical benefit as an acidifying adjunct is unproven, and high supplemental doses can increase oxalate exposure.[17][25][27]

For prescribing details shared with other pages, use the non-antibiotic UTI-prevention hub. For the operative context, see urinary diversion principles.

Urinary pH — Quick Reference​

Clinical taskTarget or interpretationImportant qualification
Uric-acid recurrence preventionAUA describes raising urine pH to 6.0Titrate to repeated urine measurements; this is not the same target as active chemolysis.[1]
Active uric-acid stone dissolutionEAU: pH 7.0–7.2Confirm likely composition, monitor imaging and urine pH; higher pH increases calcium-phosphate precipitation risk. An obstructed infected system requires drainage, not a trial of dissolution alone.[30]
CystinuriaAUA describes 7.0; EAU targets >7.5These guideline targets differ. Use the treating stone specialist's protocol, hydration and biochemical follow-up rather than a universal threshold.[1][31]
Calcium-phosphate stone formerNo universal pH targetAssess urine citrate, calcium, systemic acid–base status and supersaturation; avoid indiscriminate alkalinization while treating relevant deficits.[1][31]
MethenamineActivity depends on acidic urineThe US label has no universal numeric pH target; routine vitamin-C acidification is not recommended by AUA 2025.[27][28]
Diversion-associated acidosisSerum bicarbonate/pH, not urine pHTreatment depends on severity, symptoms, renal function and trajectory.[6][32]

1. Sodium Bicarbonate — Systemic Acidosis and Stone Disease​

Metabolic acidosis after urinary diversion​

Urine contact with intestinal mucosa can produce ammonium/chloride absorption and bicarbonate loss. Interpret acidosis alongside renal impairment, dehydration, obstruction and infection; a new deterioration should prompt investigation of its cause.[2][3][32]

What the continence study actually showed: Müller 2020 retrospectively studied 345 neobladder patients during three weeks of inpatient rehabilitation, beginning a median 29 days after surgery. Bicarbonate use increased from 45.2% to 86.7% as leakage decreased. This association supports closer early monitoring; it does not prove a universal causal rule or a lifelong medication requirement.[4]

When to treat: KDIGO 2024 advises considering treatment to prevent clinically consequential acidosis in CKD, giving serum bicarbonate <18 mmol/L as an example. It is not a diversion-specific mandatory threshold, nor an instruction to wait until 18 in a symptomatic or deteriorating postoperative patient. Monitor for excessive alkalinization, potassium changes, blood-pressure effects and fluid overload.[6][7]

Dose and duration: prescribe an individualized oral regimen and titrate to laboratory response and tolerability. A 2026 systematic review of 29 studies found heterogeneous definitions, treatment thresholds and dosing, without an established optimal prophylactic regimen; its database search ended in February 2022. A prospective controlled study of 200 selected men with uncomplicated ileal neobladders and satisfactory upper tracts found no significant biochemical advantage from continued prophylaxis versus stopping after three months. These data support reassessment rather than automatic indefinite treatment; they do not justify stopping alkali in a patient with persistent acidosis or impaired renal function.[32][33]

Historical chlorpromazine reports do not establish a contemporary routine regimen for diversion-associated acidosis. Persistent acidosis warrants reassessment and specialist management.[5]

Arrange frequent laboratory checks during early recovery and after dose changes; retain lifelong surveillance adapted to diversion type and renal risk. See vitamin B12 supplementation for the separate B12 monitoring plan.[2][6]

Choosing an alkali for stones​

Potassium citrate can address low urinary citrate and low pH; sodium bicarbonate is an alternative when potassium administration is unsuitable. Check potassium, renal function and interacting drugs before prescribing potassium citrate. Its extended-release label contraindicates use in hyperkalemia/predisposing conditions and renal insufficiency below 0.7 mL/kg/min; do not silently substitute an indexed eGFR threshold for that weight-based labeling. The label also contraindicates use with delayed or arrested gastrointestinal tablet passage, peptic ulcer disease, and active UTI associated with calcium or struvite stones.[1][8]

Sodium bicarbonate adds sodium and may worsen edema or blood-pressure control. Excess dosing can cause metabolic alkalosis, not hyperchloremia from the bicarbonate itself. Repeat serum chemistry and urine studies according to the indication.[6][8]

UTI symptom relief​

The Cochrane review found no eligible randomized trials of urinary alkalinizers for uncomplicated-UTI symptoms. This is an evidence gap, not proof of symptom benefit. Alkalinizers also oppose methenamine's acid-dependent activity.[9][28]

2. Ammonium Chloride and Distal RTA Testing​

An ammonium-chloride loading test assesses urinary acidification under a supervised systemic acid load. It is a specialist diagnostic procedure; exclude active infection and review renal function, potassium and baseline acid–base status before provocative testing. A low spot urine pH or alkaline urine alone does not diagnose or exclude every form of RTA.[10][11][13]

In Dhayat 2017, 170 stone formers underwent sequential testing. With ammonium chloride as reference and an incomplete-dRTA prevalence of 8%, the furosemide/fludrocortisone test had 77% sensitivity, 85% specificity, 30% positive predictive value and 98% negative predictive value. An abnormal screening test required confirmation. The figures are cohort-dependent and must not be rewritten as universal 100% sensitivity or 100% NPV.[13]

In the same study, fasting urine pH <5.3 together with plasma potassium >3.8 mEq/L had a 98% NPV. The acidification boundary and preparation must follow the testing protocol. Furosemide/fludrocortisone may be better tolerated, but does not eliminate the need to interpret the full clinical picture.[10][12][13]

Ammonium chloride is not a routine adjunct to methenamine. Therapeutic acidification has a limited specialist role in selected infection-stone situations; EAU grades that recommendation as weak. This should not be generalized to uncomplicated recurrent UTI or to calcium-stone formers, in whom an acid load may increase urinary calcium.[14][27][31]

3. Vitamin C — Acidification, UTI Claims and Oxalate​

Urine pH: small metabolic studies found no reliable pH reduction with 1–2 g/day, despite increased urinary oxalate. Injectable-ascorbic-acid labeling is not evidence that oral vitamin C reliably improves methenamine efficacy.[16][17][18][19]

UTI prevention: laboratory anti-biofilm, adhesion and nitric-oxide observations are mechanistic evidence. A small older pregnancy study and an uncontrolled combination-product pilot do not establish isolated vitamin-C efficacy in nonpregnant women with recurrent UTI, nor prove its mechanism in clinical practice.[15][20][21][22][23] AUA 2025 advises against routine vitamin C with methenamine; ALTAR did not evaluate supplemental acidification.[27][29]

Stone risk: Ferraro 2016 followed 197,271 participants. In men, total intake ≥1,000 mg/day was associated with an adjusted stone hazard ratio of 1.43 (95% CI 1.15–1.79) versus <90 mg/day; supplemental intake ≥1,000 mg/day had HR 1.19 (1.01–1.40) versus none. These are relative associations from observational cohorts, not absolute risks. No significant association was found in women, which does not prove high-dose supplementation is safe for every woman or for people with CKD.[25]

There is no established universal “safe ceiling” of 500 mg/day for stone formers in the cited evidence. Avoid unnecessary high-dose supplementation in calcium-oxalate stone formers and patients with renal impairment; assess dietary intake and any actual deficiency rather than prescribing vitamin C for urinary acidification. KDOQI's CKD nutrition guidance calls for individualized supplementation rather than routine high-dose use.[17][24][25][26]

Practical follow-up​

IndicationFollow the response withReconsider treatment when
Diversion acidosisSerum bicarbonate, electrolytes, renal function and clinical recoveryAcidosis worsens, sodium/fluid burden becomes problematic, or the ongoing need changes.[6][32]
Stone alkalinizationRepeated urine pH, stone burden, urine citrate/calcium and serum chemistryExcessive alkalinization, hyperkalemia, intolerance or recurrent stones despite the apparent target.[1][8][30]
Methenamine preventionSymptomatic/culture-confirmed recurrence, tolerance and relevant contraindicationsRecurrent symptoms require reassessment; do not simply escalate acidifying supplements.[27][28]

See Also​

References​

1. Pearle MS, Goldfarb DS, Assimos DG, et al. "Medical management of kidney stones: AUA guideline." J Urol. 2014;192(2):316–324. doi:10.1016/j.juro.2014.05.006

2. Lenis AT, Lec PM, Chamie K, et al. "Bladder cancer: a review." JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598

3. Berend K, de Vries AP, Gans RO. "Physiological approach to assessment of acid-base disturbances." N Engl J Med. 2014;371(15):1434–1445. doi:10.1056/NEJMra1003327

4. Müller G, Butea-Bocu M, Brock O, et al. "Association between development of metabolic acidosis and improvement of urinary continence after ileal neobladder creation." J Urol. 2020;203(3):585–590. doi:10.1097/JU.0000000000000583

5. Koch MO, McDougal WS. "Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments." J Urol. 1985;134(1):165–169. doi:10.1016/s0022-5347(17)47049-2

6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. "KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease." Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018

7. Navaneethan SD, Bansal N, Cavanaugh KL, et al. "KDOQI US commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD." Am J Kidney Dis. 2025;85(2):135–176. doi:10.1053/j.ajkd.2024.08.003

8. US prescribing information. Potassium citrate extended-release tablets. DailyMed label. Accessed September 11, 2026.

9. O'Kane DB, Dave SK, Gore N, et al. "Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women." Cochrane Database Syst Rev. 2016;4:CD010745. doi:10.1002/14651858.CD010745.pub2

10. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. "Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride." Kidney Int. 2007;71(12):1310–1316. doi:10.1038/sj.ki.5002220

11. Alexander RT, Gil-Peña H, Greenbaum LA, et al. Hereditary Distal Renal Tubular Acidosis. GeneReviews. Updated 2025-04-03.

12. Shavit L, Chen L, Ahmed F, et al. "Selective screening for distal renal tubular acidosis in recurrent kidney stone formers: initial experience and comparison of the simultaneous furosemide and fludrocortisone test with the short ammonium chloride test." Nephrol Dial Transplant. 2016;31(11):1870–1876. doi:10.1093/ndt/gfv423

13. Dhayat NA, Gradwell MW, Pathare G, et al. "Furosemide/fludrocortisone test and clinical parameters to diagnose incomplete distal renal tubular acidosis in kidney stone formers." Clin J Am Soc Nephrol. 2017;12(9):1507–1517. doi:10.2215/CJN.01320217

14. Lennon EJ, Piering WF. "A comparison of the effects of glucose ingestion and NH4Cl acidosis on urinary calcium and magnesium excretion in man." J Clin Invest. 1970;49(7):1458–1465. doi:10.1172/JCI106363

15. Habash MB, Van der Mei HC, Busscher HJ, Reid G. "The effect of water, ascorbic acid, and cranberry derived supplementation on human urine and uropathogen adhesion to silicone rubber." Can J Microbiol. 1999;45(8):691–694. doi:10.1139/w99-065

16. US Food and Drug Administration. ASCOR (ascorbic acid injection): labeling in 2024 supplement review. FDA record.

17. Traxer O, Huet B, Poindexter J, Pak CY, Pearle MS. "Effect of ascorbic acid consumption on urinary stone risk factors." J Urol. 2003;170(2 Pt 1):397–401. doi:10.1097/01.ju.0000076001.21606.53

18. Baxmann AC, De O G Mendonça C, Heilberg IP. "Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients." Kidney Int. 2003;63(3):1066–1071. doi:10.1046/j.1523-1755.2003.00815.x

19. Nahata MC, Cummins BA, McLeod DC, Schondelmeyer SW, Butler R. "Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy." Eur J Clin Pharmacol. 1982;22:281–284. doi:10.1007/BF00545228.

20. Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO. "Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine." Nitric Oxide. 2001;5(6):580–586. doi:10.1006/niox.2001.0371

21. Hassuna NA, Rabie EM, Mahd WKM, et al. "Antibacterial effect of vitamin C against uropathogenic E. coli in vitro and in vivo." BMC Microbiol. 2023;23(1):112. doi:10.1186/s12866-023-02856-3

22. Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, et al. "Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy." Acta Obstet Gynecol Scand. 2007;86(7):783–787. doi:10.1080/00016340701273189

23. Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. "Effectiveness of a combination of cranberries, Lactobacillus rhamnosus, and vitamin C for the management of recurrent urinary tract infections in women: results of a pilot study." Eur Urol. 2016;70(6):912–915. doi:10.1016/j.eururo.2016.05.042

24. Massey LK, Liebman M, Kynast-Gales SA. "Ascorbate increases human oxaluria and kidney stone risk." J Nutr. 2005;135(7):1673–1677. doi:10.1093/jn/135.7.1673

25. Ferraro PM, Curhan GC, Gambaro G, Taylor EN. "Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones." Am J Kidney Dis. 2016;67(3):400–407. doi:10.1053/j.ajkd.2015.09.005

26. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. "KDOQI clinical practice guideline for nutrition in CKD: 2020 update." Am J Kidney Dis. 2020;76(3 Suppl 1):S1–S107. doi:10.1053/j.ajkd.2020.05.006

27. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)." J Urol. 2025. doi:10.1097/JU.0000000000004723. Full guideline, statements 12–17.

28. Validus Pharmaceuticals LLC. HIPREX (methenamine hippurate tablets USP): US prescribing information. July 2021; DailyMed record revised February 2022. Prescribing information. Accessed September 11, 2026.

29. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229.

30. European Association of Urology. Urolithiasis: oral chemolysis. 2026 online guideline. Guideline. Accessed September 11, 2026.

31. European Association of Urology. Urolithiasis: metabolic evaluation and recurrence prevention. 2026 online guideline. Guideline. Accessed September 11, 2026.

32. Desai S, Frisbie J, Moreton E, et al. Systematic review: The role of bicarbonate therapy after urinary diversion. Bladder Cancer. 2026;12(1). doi:10.1177/23523735261424587. Full text. Search through February 2022; heterogeneous observational evidence.

33. Mahmoud O, El-Assmy A, Kamal M, Ashamallah A, Abol-Enein H. Is chronic alkali therapy in orthotopic ileal neobladders necessary? A prospective controlled study. Int Urol Nephrol. 2017;49:49–53. doi:10.1007/s11255-016-1447-0. PubMed.